271 related articles for article (PubMed ID: 25572799)
1. Effects of donor/recipient human leukocyte antigen mismatch on human cytomegalovirus replication following liver transplantation.
Aldridge RW; Mattes FM; Rolando N; Rolles K; Smith C; Shirling G; Atkinson C; Burroughs AK; Milne RS; Emery VC; Griffiths PD
Transpl Infect Dis; 2015 Feb; 17(1):25-32. PubMed ID: 25572799
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus and cancer after kidney transplantation: Role of the human leukocyte antigen system?
Wong G; Chakera A; Chapman JR; Chadban SC; Pilmore H; Craig JC; Lim WH
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27860123
[TBL] [Abstract][Full Text] [Related]
3. CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus.
Mikulska M; Raiola AM; Bruzzi P; Varaldo R; Annunziata S; Lamparelli T; Frassoni F; Tedone E; Galano B; Bacigalupo A; Viscoli C
Biol Blood Marrow Transplant; 2012 Jan; 18(1):92-9. PubMed ID: 21689774
[TBL] [Abstract][Full Text] [Related]
4. Three-year survival rates for all consecutive heart-only and lung-only transplants performed in Eurotransplant, 1997-1999.
Smits JM; Vanhaecke J; Haverich A; de Vries E; Smith M; Rutgrink E; Ramsoebhag A; Hop A; Persijn G; Laufer G
Clin Transpl; 2003; ():89-100. PubMed ID: 15387100
[TBL] [Abstract][Full Text] [Related]
5. Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.
Shabir S; Kaul B; Pachnio A; Banham GD; Smith H; Chand S; Jham S; Harper L; Ball S; Rahbar A; Söderberg-Nauclér C; Moss P; Borrows R
J Am Soc Nephrol; 2013 Oct; 24(10):1698-708. PubMed ID: 23847277
[TBL] [Abstract][Full Text] [Related]
6. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
[TBL] [Abstract][Full Text] [Related]
7. The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation.
Mañez R; White LT; Linden P; Kusne S; Martin M; Kramer D; Demetris AJ; Van Thiel DH; Starzl TE; Duquesnoy RJ
Transplantation; 1993 May; 55(5):1067-71. PubMed ID: 8388584
[TBL] [Abstract][Full Text] [Related]
8. The impact of donor viral replication at transplant on recipient infections posttransplant: a prospective study.
Verghese PS; Schmeling DO; Knight JA; Matas AJ; Balfour HH
Transplantation; 2015 Mar; 99(3):602-8. PubMed ID: 25148381
[TBL] [Abstract][Full Text] [Related]
9. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
Singh N; Wannstedt C; Keyes L; Mayher D; Tickerhoof L; Akoad M; Wagener MM; Cacciarelli TV
Liver Transpl; 2008 Feb; 14(2):240-4. PubMed ID: 18236404
[TBL] [Abstract][Full Text] [Related]
10. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
11. Association of cytomegalovirus infection with human leukocyte antigen genotypes in recipients after allogeneic liver transplantation.
Fan J; Meng XQ; Yang MF; Zhou L; Chen XM; Hu MJ; Fan WW; Ma WH; Li LJ
Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):34-8. PubMed ID: 16481279
[TBL] [Abstract][Full Text] [Related]
12. Human leukocyte antigen compatibility and lymphocyte cross-matching play no significant role in the current adult-to-adult living donor liver transplantation.
Badawy A; Kaido T; Yoshizawa A; Yagi S; Fukumitsu K; Okajima H; Uemoto S
Clin Transplant; 2018 Apr; 32(4):e13234. PubMed ID: 29499077
[TBL] [Abstract][Full Text] [Related]
13. Unexpected Cytomegalovirus (CMV) Replication Kinetics in CMV Donor-Seropositive, Recipient-Seronegative Liver Transplant Recipients Receiving Preemptive Antiviral Therapy.
Singh N; Winston DJ; Razonable RR; Marshall Lyon G; Silveira FP; Wagener MM; Limaye AP
J Infect Dis; 2022 Feb; 225(3):436-442. PubMed ID: 33755176
[TBL] [Abstract][Full Text] [Related]
14. Recipient-donor KIR ligand matching prevents CMV reactivation post-haploidentical T cell-replete transplantation.
Zhao XY; Luo XY; Yu XX; Zhao XS; Han TT; Chang YJ; Huo MR; Xu LP; Zhang XH; Liu KY; Li D; Jiang ZF; Huang XJ
Br J Haematol; 2017 Jun; 177(5):766-781. PubMed ID: 28466469
[TBL] [Abstract][Full Text] [Related]
15. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status.
Servais S; Dumontier N; Biard L; Schnepf N; Resche-Rigon M; Peffault de Latour R; Scieux C; Robin M; Meunier M; Xhaard A; Sicre de Fontbrune F; Le Goff J; Socié G; Simon F; Mazeron MC
Clin Microbiol Infect; 2016 Mar; 22(3):289.e1-7. PubMed ID: 26627339
[TBL] [Abstract][Full Text] [Related]
16. Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort.
Meije Y; Fortún J; Len Ó; Aguado JM; Moreno A; Cisneros JM; Gurguí M; Carratalà J; Muñoz P; Montejo M; Blanes M; Bou G; Pérez JL; Torre-Cisneros J; Ramos A; Pahissa A; Gavaldà J;
Transpl Infect Dis; 2014 Jun; 16(3):387-96. PubMed ID: 24807640
[TBL] [Abstract][Full Text] [Related]
17. Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis.
Limaye AP; Green ML; Edmison BC; Stevens-Ayers T; Chatterton-Kirchmeier S; Geballe AP; Singh N; Boeckh M
J Infect Dis; 2019 Jul; 220(5):752-760. PubMed ID: 31112280
[TBL] [Abstract][Full Text] [Related]
18. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST
Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799
[TBL] [Abstract][Full Text] [Related]
19. Association of human cytomegalovirus viremia with human leukocyte antigens in liver transplantation recipients.
Hu J; Meng X; Zhao H; Zhang X; Gao H; Yang M; Ma Y; Li M; Ma W; Fan J
Acta Biochim Biophys Sin (Shanghai); 2011 Jul; 43(7):576-81. PubMed ID: 21680603
[TBL] [Abstract][Full Text] [Related]
20. Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients.
Sun HY; Cacciarelli TV; Wagener MM; Singh N
Transpl Immunol; 2010 Aug; 23(4):166-9. PubMed ID: 20609386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
